F Novelli, Y Yoshikawa, VAM Vitto, L Modesti… - Proceedings of the …, 2024 - pnas.org
We report that~ 1.8% of all mesothelioma patients and 4.9% of those younger than 55, carry rare germline variants of the BRCA1 associated RING domain 1 (BARD1) gene that were …
K Agiannitopoulos, K Potska, A Katseli, C Ntogka… - Cancers, 2023 - mdpi.com
Simple Summary The aim of this study was to explore the utility of cascade family testing (CFT) in families of breast cancer patients who carry specific genetic variations. We …
N Tsoulos, K Agiannitopoulos, K Potska… - Cancer Genomics & …, 2024 - cgp.iiarjournals.org
Background/Aim: The application of next-generation sequencing (NGS) technology in the genetic investigation of hereditary cancer is important for clinical surveillance, therapeutic …
Simple Summary In patients with epithelial ovarian cancer, the gold standard Myriad MyChoice® CDx assay is used to assess homologous recombination deficiency (HRD), as a …
N Tsoulos, E Papadopoulou, K Agiannitopoulos… - Diagnostics, 2024 - mdpi.com
Breast cancer (BC) is the most prominent tumor type among women, accounting for 32% of newly diagnosed cancer cases. BC risk factors include inherited germline pathogenic gene …
K Agiannitopoulos, K Potska, A Katseli… - doi. org/10.3390 …, 2023 - genekor.com
Background: Hereditary cancer predisposition syndromes are responsible for approximately 5–10% of all diagnosed cancer cases. In order to identify individuals at risk in a costefficient …
K Potska, A Katseli, K Agiannitopoulos, C Ntogka… - 2024 - preprints.org
Pancreatic cancer stands out as one of the most lethal forms of malignancies, representing 2% of all cancer cases and contributing to 5% of cancer-related fatalities. Therefore, early …
Κ Agiannitopoulos, Κ Potska, Ν Katseli, C Ntogka… - genekor.com
Methods In total, 7,787 individuals were referred for multi gene genetic testing, in the period 2020-2023, to the Genekor laboratory and genetic testing using NGS was performed (Figure …